Phase 2 N=33 Study of Combined Fulvestrant and Everolimus in Advanced/Metastatic Breast Cancer After Aromatase Inhibitor Failure
Breast Cancer
Primary: Time to Progression — 7.4 months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=41 A Study of Ramucirumab (IMC-1121B) With Paclitaxel and Carboplatin in Non-small Cell Lung Cancer
Non Small Cell Lung Cancer
Primary: Percentage of Participants Who Are Progression-free (PFS) at 6 Months — 59.0 percentage of participants
Phase 2 N=280 A Study of Pemetrexed and Carboplatin/Cisplatin or Gemcitabine and Carboplatin/Cisplatin With or Without IMC-1121B in Participants Previously Untreated With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)
Carcinoma, Non-Small-Cell Lung
Primary: Progression-Free Survival (PFS) — 5.6; 7.2; 5.4; 5.6 months — p=0.1318
Phase 2 N=24 Effect of Resveratrol Administration on Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion
Metabolic Syndrome X
Primary: Triglycerides Levels at Week 12 — 210.6; 235.8 mg/dL — p=0.131
Phase 2 N=13 PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery
Advanced Malignant Mesothelioma · Epithelial Mesothelioma · Recurrent Malignant Mesothelioma
Primary: Objective Tumor Response Rate According to the Response Evaluation Criteria in Solid Tumors (RECIST) Committee — 0 percentage of participants
Phase 2 N=41 A Phase I/II Clinical Trial of PXD101 in Combination With Doxorubicin in Patients With Soft Tissue Sarcomas
Dose Escalation: Solid Tumors · MTD: Soft Tissue Sarcomas
Primary: Maximum Tolerated Dose (MTD) PXD101 — 1000 mg/m²
Phase 2 N=51 Haemophilia Patients With Inhibitors Being Treated for Acute Joint Bleeds
Congenital Bleeding Disorder · Haemophilia A · Haemophilia B
Primary: Number of Adverse Events (AEs) — 10; 8; 5; 5 events
Phase 2 N=20 F-18 16 Alpha-Fluoroestradiol-Labeled Positron Emission Tomography in Predicting Response to First-Line Hormone Therapy in Patients With Stage IV Breast Cancer
Estrogen Receptor-positive Breast Cancer · Progesterone Receptor-negative Breast Cancer · Progesterone Receptor-positive Breast Cancer
Primary: Best Overall Response — 5; 2 patients with progressive disease
Phase 2 N=45 Somatostatin Analogue SOM230 (Pasireotide) in Healthy Male Volunteers
Hyperglycemia
Primary: Change in Insulin Basal Level — -24.37; -29.60 pmol/L — p=<0.001
Phase 2 N=21 Paired Psoriasis Lesion, Comparative, Study to Evaluate MOL4239 in Psoriasis
Psoriasis
Primary: Mean Change From Baseline to Day 28 in PSS (Psoriasis Severity Score) of the Treatment Target Lesions Compared to Placebo Target Lesions — -1.9; -1.5 PSS score
Phase 2 N=60 F-18 Sodium Fluoride in Prostate Cancer
Prostate Neoplasm
Primary: Number of Participants With Present or Not Present Bone Metastasis — 30; 10; 0; 20 Participants
Phase 2 N=23 Gefitinib in Treating Patients Who Are Undergoing Surgery and/or Radiation Therapy for Locally Advanced or Recurrent Squamous Cell Skin Cancer
Recurrent Skin Cancer · Squamous Cell Carcinoma of the Skin
Primary: Early Progression Rate — 31.8 percentage of participants
Phase 2 N=159 Granulocyte-Macrophage Stimulating Factor in the Treatment of Peripheral Arterial Disease
Peripheral Arterial Disease
Primary: Change in Peak Walking Time During Treadmill Exercise Tolerance Test From Baseline to 3 Months — 109; 56 seconds
Phase 2 N=30 Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
Acral Lentiginous Malignant Melanoma · Recurrent Melanoma · Stage IIIA Melanoma
Primary: Objective Response Rate — 1; 3; 14; 7 participants
Phase 2 N=42 Yttrium-90 Radioembolization Using Glass Microspheres (TheraSphere) for Patients With Liver Metastases
Colorectal Neoplasms · Neuroendocrine Tumors · Cholangiocarcinoma
Primary: Number of Participants With Adverse Events — 42 participants